A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ANTROQUINONOL IN HOSPITALIZED PATIENTS WITH MILD TO MODERATE PNEUMONIA DUE TO COVID-19
- Conditions
- -J128 Other viral pneumoniaOther viral pneumoniaJ128
- Registration Number
- PER-090-20
- Lead Sponsor
- Golden Biotechnology Corporation,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 23
1. Willing and able to provide informed consent.
2. Male or female patients between 18 and 80 years of age.
3. Hospitalized with mild COVID-19 disease (not requiring oxygen therapy [WHO COVID-19 Clinical Improvement Ordinal Scale, score of 3] or requiring oxygen therapy by mask or nasal prong [WHO COVID-19 Clinical Improvement Ordinal Scale, score of 4]).
Note: Hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat COVID-19 patients.
4. Chest x- ray or computerized tomography (CT) scan consistent with pneumonia.
5. Onset of COVID-19 symptoms within 2 weeks prior to randomization.
6. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection confirmed by a polymerase chain reaction (PCR) test (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing).
7. Male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception.
8. Female patients of childbearing potential must have a negative pregnancy test at Screening or pretreatment on Day 1.
9. Male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from Day 1 until 90 days after the last dose of study treatment.
10. Patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.
1. Female patient is pregnant or breastfeeding.
2. Any patient’s concomitant life-threatening condition, including but not limited to: requiring mechanical ventilation, acute respiratory distress syndrome, shock, or cardiac failure.
3. Evidence of multi-lobar consolidation pneumonia or cavities on chest x-ray or CT scan.
4. Severe COVID-19 disease as defined by the WHO COVID-19 Clinical Improvement Ordinal Scale, scores of 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation), or 7 (ventilation + additional organ support-pressors, renal replacement therapy, ECMO).
5. Medical history significant for the following pulmonary diseases: lung cancer, cystic fibrosis, empyema.
6. Respiratory rate >30 respirations per minute.
7. History of abuse of drugs or alcohol that could interfere with adherence to study requirements, as judged by the investigator.
8. Treatment with other drugs thought to possibly have activity against COVID-19 within 7 days prior to enrollment or concurrently. Note: remdesivir or other authorized treatments for COVID-19 is allowed if considered SoC, if started prior to randomization or during the study.
9. Use of other investigational drugs within 30 days of dosing, or plans to enroll in another clinical trial of an investigational agent while participating in the present study.
10. Use of Antrodia camphorata -containing products within 2 weeks prior to the first administration of study drug.
11. Clinically significant abnormal electrocardiogram (ECG) at Screening, as determined by the investigator.
12. Patient requires frequent or prolonged use of systemic corticosteroids (≥20 mg of prednisone/day or equivalent for >4 weeks) or other immunosuppressive drugs (e.g., for organ transplantation or autoimmune conditions).
13. Abnormal laboratory values at Screening:
a. Estimated glomerular filtration rate <50 mL/min.
b. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 × upper limit of normal (ULN), or ALT/AST >3 × ULN plus total bilirubin >2 × ULN.
c. Total bilirubin >1.5 × ULN, unless the patient has known Gilbert’s syndrome.
d. Hemoglobin <9 g/dL for females or <11 g/dL for males.
e. Absolute neutrophil count <1,500/mm3.
f. Thrombocytopenia (platelets count <100 × 109/L).
14. Treatment with any antiviral drugs (except remdesivir or other authorized treatments for COVID-19), or with any drugs known to be strong inducers or inhibitors of cytochrome P450 isoform (CYP) 2C19, CYP3A4, CYP2C8, and CYP2E1 within 14 days or 5 half-lives prior to the start of study treatment. Drugs with a narrow therapeutic index that are substrates of 1A2, 2B6, 2C8, 2C9, 2C19, 3A, and 2D6 are also prohibited.
15. Inability to swallow oral medications or a gastrointestinal disorder with diarrhea (e.g., Crohn’s disease), malabsorption, or diarrhea of any etiology at baseline.
16. Any other clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, would jeopardize the safety of the patient or potentially impact patient compliance or the safety/efficacy observations in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br>Outcome name:The proportion of patients who are alive and free of respiratory failure (e.g., no need for invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO)<br>Measure:Efficacy<br>Timepoints:Day 14<br>
- Secondary Outcome Measures
Name Time Method